A shadow market for unlicensed slimming medications is being driven by social media fitness personalities and sellers on messaging platforms, according to new investigations.
Investigational Treatment Gaining Traction Via Social Media
The experimental drug, which remains in clinical trials, is being advertised by social media influencers for its alleged weight-reducing effects. Followers are encouraged to contact these accounts directly for supplier links, while also obtaining discount codes.
Active Commerce on Social Networks
Additionally, a robust market exists on Telegram, where groups with thousands of members share “before and after” photos, injection guides and assertions of next-day UK delivery. Vendors market the drug there before redirecting customers to other platforms for purchases.
Learning About The Experimental Drug
Retatrutide is an experimental injectable created by US drugmaker Eli Lilly. The treatment targets three intestinal hormones – glucagon-like peptide-1, GIP and glucagon. Preliminary studies suggest it could assist individuals reduce up to a quarter of their total weight. Referred to as the “triple G”, the drug is being hailed digitally as the next Ozempic.
Healthcare Professionals Voice Worries
However, physicians and pharmacists have warned that the sale of what is still an unlicensed medication in the United Kingdom is a cause for concern and could result in users injecting products of uncertain source.
Some professionals said the popularity for retatrutide could be linked to the rising cost of licensed weight loss products such as Mounjaro.
Legal Status and Implementation
Selling retatrutide on TikTok or messaging apps is illegal in the UK, as it is an unlicensed drug that cannot be marketed or distributed for personal consumption under the British medical regulations.
Some content creators try to circumvent the regulations by referring to the drug as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a restricted drug, but promotion and distribution can still breach medicines, marketing, and consumer laws, risking fines, prosecution or imprisonment.
Platform Response and Content Removal
Based on the social media company, the service has taken down problematic material and prohibited associated keywords and query recommendations. The company said it was committed to maintaining the service safe and allocating resources in enhancing compliance measures.
Online Marketplace Operations
Investigations also found groups with up to 9,000 members selling the experimental drug using Telegram's integrated discovery tool, which operates like a public directory. Entering “retatrutide” instantly displays channels with thousands of members, populated with images of weight loss, positive testimonials and step-by-step instructions for preparing or administering at residence.
After moments of joining one group, a vendor shared WhatsApp details, where the majority of purchases occur. The vendor provided an guidebook and guaranteed shipping within two days. When questioned whether the product was authentic, one seller said: “You can’t be sure.” Another shared a image of a alleged laboratory certificate. None asked about weight, medical conditions or previous experience.
Item Information and Costs
Inside these groups, messages show dark colored parcels with postal service labels, stating to contain new batches. One message stated: “It took eight of us to load them this morning.”
Customers can choose between dry substance containers, mixed at residence with purified liquid, or ready-to-use injectors usually priced at £160 for 20mg. When questioned how much time a injector should last, vendors give conflicting responses varying between a several days to “depends on your body”.
Platform Oversight and Safety Actions
A representative for Telegram stated it regularly monitored harmful content on its platform including material that promoted the “misuse of controlled medications”. The company added that it removed “millions of pieces of harmful content each day”.
Healthcare Expert Warnings
“Individuals are administering substances they cannot confirm. Even if the research behind retatrutide is valid, these digital products may not contain what they claim,” stated Jason Murphy, the director of pharmacy at Chemist4U.
Dr Crystal Wyllie of an online medical service linked the increase in interest to current cost increases for authorized slimming drugs such as Mounjaro. “With prices rising, patients are turning to online platforms. But counterfeit treatments are highly risky. You cannot know what’s contained or whether the environment they were produced in was sterile,” she explained.
Her team has already seen patients injured by personal administration from unverified suppliers. “We recognize the frustration, but purchasing from messaging apps or WhatsApp is taking chances with your health,” said the doctor. “These materials could be impure or improperly measured.”
Producer Position
A representative from Eli Lilly said the substance was in phase 3 clinical trials and had not been evaluated or approved by any regulatory agency anywhere in the world. “Consequently at this time no one can sell [it] for human use,” they said, adding that any item “misleadingly claiming itself as a Lilly investigational substance not yet authorized … may expose users to potentially serious medical dangers”.
